Search

everythinglearnresearchcommunity

for

Search:↓

Booster shots of mRNA vaccines for COVID-19 increased protective antibodies without worsening autoimmune skin conditions in patients.

IL-4 and IL-13 might play a role in a type of hair loss similar to alopecia areata.

Vitiligo and alopecia areata may have similar causes despite their differences.

Flammulina velutipes polysaccharide helps the immune system fight tumors by activating certain pathways.

A vitamin D receptor mutation causes rickets and affects immune responses.

Acne patients' skin, both with and without lesions, shows a strong immune response and higher antimicrobial activity.

Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.

People with atopic dermatitis have more CD4+ T cells that respond to a certain bacterial lipid, which may play a role in the skin condition's inflammation.

The role of γδT-cells in causing alopecia areata remains unclear.

Hair loss may link to weaker COVID-19 immunity, suggesting possible need for extra vaccine boost.

TNC+ fibroblasts play a key role in skin inflammation by interacting with T cells.

Chronic graft-versus-host disease in the skin shows strong Th1 immune response and unique barrier issues.

Fzd2 is important for skin and hair development through various signaling ways.

NKG2D+CD4+ T cells are higher in alopecia areata patients and may be involved in the disease.

Dupilumab can help regrow hair in alopecia areata but stopping it may cause hair loss again.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.

Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.

Genetically at-risk healthy people show similar immune issues as those with Pemphigus vulgaris or Alopecia areata.

Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Activating TLR9 helps heal wounds and regrow hair by using specific immune cells.

Using anthralin and calcipotriene together might help treat tough cases of alopecia areata, but more research is needed to understand how it works.

Platelet-rich plasma may help restore immune balance in bald patches, but its effectiveness in treating hair loss is limited.

A teenager had both alopecia areata and vitiligo, which are rare to occur together.

Certain gene changes in osteopontin are linked to higher risk of atopic dermatitis and asthma.

Blocking TYK2 might be a new way to treat hair loss from alopecia areata.

Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.

People with alopecia areata have fewer IL-10 producing immune cells, which might contribute to the condition.

IL-17 inhibitors for psoriasis may cause unexpected hair loss.